Cellular Immunotherapy
Showing 1 - 25 of 6,052
Septic Shock, Sepsis, Pathologic Processes Trial (Allogeneic umbilical cord-derived human mesenchymal stromal cells, Placebo)
Not yet recruiting
- Septic Shock
- +6 more
- Allogeneic umbilical cord-derived human mesenchymal stromal cells
- Placebo
- (no location specified)
Aug 3, 2023
Progressive Multifocal Leukoencephalopathy Trial run by the National Institute of Neurological Disorders and Stroke (NINDS)
Completed
- Progressive Multifocal Leukoencephalopathy
- PyVST
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Cholangiocarcinoma Trial in Beijing (autologous Tcm cellular immunotherapy)
Recruiting
- Cholangiocarcinoma
- autologous Tcm cellular immunotherapy
-
Beijing, ChinaPeking Union Medical College Hospital
Apr 24, 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in Oklahoma City (Sipuleucel-T)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sipuleucel-T
-
Oklahoma City, OklahomaStephenson's Cancer Center
Mar 28, 2023
Recipients Who Previously Received Medeor's Cellular
Recruiting
- Immune Tolerance
- MDR product
-
New Haven, ConnecticutYale University
Apr 18, 2022
Following Treatment With Fate Therapeutics' Engineered Cellular
Terminated
- Hematological Malignancy
- Genetically engineered NK cells
-
Phoenix, Arizona
- +4 more
Aug 24, 2022
Kidney Transplant Rejection Trial (MDR-103)
Not yet recruiting
- Kidney Transplant Rejection
- MDR-103
- (no location specified)
Apr 4, 2022
Kidney Transplant Rejection Trial (MDR-102, Immunosuppressive Agents)
Not yet recruiting
- Kidney Transplant Rejection
- MDR-102
- Immunosuppressive Agents
- (no location specified)
Apr 4, 2022
COVID-19 Trial in Vandœuvre-lès-Nancy (Generation of a biobank allowing the cryopreservation of leucocytes from COVID19
Not yet recruiting
- COVID-19
- Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors
-
Vandœuvre-lès-Nancy, Lorraine, FranceCHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton
Aug 17, 2022
Urinary Bladder Tumor Trial in Beijing (autologous Tcm cells immunotherapy)
Terminated
- Urinary Bladder Neoplasm
- autologous Tcm cells immunotherapy
-
Beijing, ChinaHuanxing ward, Cancer Hospital Chinese Academy of Medical Scienc
Nov 19, 2021
Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis Trial in Nanjing (collection of peripheral blood
Terminated
- Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis
- collection of peripheral blood mononuclear cells from healthy volunteers
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Dec 17, 2021
Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma Trial in Providence (cellular immunotherapy)
Terminated
- Mantle Cell Lymphoma
- +4 more
- cellular immunotherapy
-
Providence, Rhode Island
- +1 more
Feb 23, 2022
Kidney Transplant Rejection Trial in Canada, United States (MDR-101)
Active, not recruiting
- Kidney Transplant Rejection
- MDR-101
-
La Jolla, California
- +19 more
Aug 22, 2022
Healthy Subject Trial in Shanghai (Peripheral blood mononuclear cell apheresis)
Recruiting
- Healthy Subject
- Peripheral blood mononuclear cell apheresis
-
Shanghai, ChinaZhaxin Hospital of Integrated Traditional Chinese and Western Me
Jun 7, 2021
Long-term, Non-interventional, Observational Study Following
Recruiting
- Advanced Solid Tumor
- +17 more
- Allogeneic natural killer (NK) cell
-
San Diego, California
- +3 more
Oct 15, 2021
Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Anti-CD33 CAR T-cells
- Lymphodepletion Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte
Recruiting
- Malignant Neoplasm
- +4 more
- Chimeric Antigen Receptor T-Cell Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 14, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Mexico City (SV-102)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
-
Mexico City, MexicoHospital Diomed
Sep 14, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
B Cell Leukemia Trial in Seattle (Autologous CD19 CAR+ EGFTt + T cells)
Active, not recruiting
- B Cell Leukemia
- Autologous CD19 CAR+ EGFTt + T cells
-
Seattle, WashingtonSeattle Children's Hospital
Feb 15, 2022
Malignant Brain Tumor, Recurrent Malignant Brain Tumor, Refractory Malignant Brain Tumor Trial in Duarte (Cyclophosphamide,
Recruiting
- Malignant Brain Neoplasm
- +2 more
- Cyclophosphamide
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 19, 2022
Hepatocellular Carcinoma Trial in Beijing (adoptive immunotherapy, MWA)
Completed
- Hepatocellular Carcinoma
- adoptive immunotherapy
- MWA
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Mar 2, 2021
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 Trial in Seattle (drug, other, biological, radiation)
Terminated
- Merkel Cell Polyomavirus Infection
- Stage IV Merkel Cell Carcinoma AJCC v7
- Avelumab
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 25, 2022
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in
Recruiting
- Diffuse Large-Cell Lymphoma
- +3 more
- Pneumococcal conjugate vaccine (PCV13)
- CD19 targeted CAR T Cell Therapy
-
Tampa, FloridaMoffitt Cancer Center
May 31, 2022